Zoetis Inc. $ZTS Shares Sold by Corient Private Wealth LLC

Corient Private Wealth LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,303,983 shares of the company’s stock after selling 82,770 shares during the period. Corient Private Wealth LLC owned 0.29% of Zoetis worth $203,356,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of ZTS. Savvy Advisors Inc. grew its stake in shares of Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after buying an additional 1,114 shares during the period. Sound Income Strategies LLC raised its position in shares of Zoetis by 54.3% during the 2nd quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after buying an additional 152 shares during the period. Canoe Financial LP lifted its holdings in Zoetis by 859.0% in the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock valued at $2,085,000 after acquiring an additional 11,975 shares during the last quarter. Strs Ohio purchased a new position in Zoetis in the first quarter worth approximately $22,891,000. Finally, Chicago Partners Investment Group LLC grew its position in Zoetis by 67.0% in the second quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after acquiring an additional 1,961 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS opened at $118.60 on Monday. The stock’s 50-day moving average price is $130.95 and its 200 day moving average price is $145.94. Zoetis Inc. has a 12-month low of $115.25 and a 12-month high of $181.85. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The firm has a market cap of $52.26 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 2.46 and a beta of 0.97.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating the consensus estimate of $1.62 by $0.08. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.Zoetis’s revenue was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s payout ratio is currently 33.67%.

Analyst Upgrades and Downgrades

ZTS has been the topic of a number of research analyst reports. Barclays assumed coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a research report on Wednesday, December 3rd. JPMorgan Chase & Co. reduced their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a report on Wednesday, November 5th. KeyCorp assumed coverage on shares of Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, Stifel Nicolaus dropped their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research report on Tuesday, November 18th. Five research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, Zoetis currently has a consensus rating of “Hold” and a consensus target price of $164.20.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.